Please assess the completion status of the following clinical trial:

Trial Title: First in Human Single Ascending Dose Study of MOR107

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 11.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Healthy males~2. Age 18 to 45 years of age~3. Body mass index of 18.0 to 32.0 kg/m2~4. For Part 2, subjects must have at least a 25% reduction in 24 hour urinary sodium excretion on Day -2 compared with admission~Key Exclusion Criteria:~1. Subjects who have received any IMP in a clinical research study within the previous three months~2. Regular alcohol consumption \>21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)~3. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening/admission~4. Current smokers of e-cigarettes and nicotine replacement products and those who have smoked these products within the last 12 months~5. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator~6. Positive drugs of abuse test result~7. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results~8. History of psychiatric disorder, cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the investigator~9. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Part 1, MOR107 Dose level 1 (Type: EXPERIMENTAL): MOR107, single subcutaneous injection
- Part 1, MOR107 Dose level 2 (Type: EXPERIMENTAL): MOR107, single subcutaneous injection
- Part 1, MOR107 Dose level 3 (Type: EXPERIMENTAL): MOR107, single subcutaneous injection
- Part 1, MOR107 Dose level 4 (Type: EXPERIMENTAL): MOR107, single subcutaneous injection
- Part 1, MOR107 Dose level 5 (Type: EXPERIMENTAL): MOR107, single subcutaneous injection
- Part 1, MOR107 Dose level 6 (Type: EXPERIMENTAL): MOR107, single subcutaneous injection
- Part 1, Placebo (Type: PLACEBO_COMPARATOR): Placebo, single subcutaneous injection
- Part 2: MOR107 low dose (Type: EXPERIMENTAL): MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
- Part 2: MOR107 medium dose (Type: EXPERIMENTAL): MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
- Part 2: MOR107 high dose (Type: EXPERIMENTAL): MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility